Skip to main content
SpringerLink
Log in

Stimulant Pharmacotherapy for Adults with ADHD

  • Chapter
  • First Online:
ADHD in Adults

Part of the book series: Current Clinical Psychiatry ((CCPSY))

Abstract

This chapter is a review of stimulant treatment for attention deficit hyperactivity disorder (ADHD) in adults, drawing on the clinical literature, emerging guidelines on the topic, and clinical experience. The chapter includes a practical approach to initiating therapy and recommendations on monitoring for effectiveness and for adverse effects. Special emphasis is given to the cardiovascular impact of stimulants and related clinical recommendations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Plizka S. AACAP practice parameter for the assessment and treatment of children and ­adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921.

    Article  Google Scholar 

  2. CADDRA. Canadian ADHD practice guidelines; 2011. http://www.caddra.ca/cms4/. Accessed 15 Apr 2011.

  3. NICE. Clinical guideline; 2008. http://www.nice.org.uk/. Accessed 15 Apr 2011.

  4. Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007;21(1):10–41.

    Article  PubMed  CAS  Google Scholar 

  5. Wood DR, Reimherr FW, Wender PH, Johnson GE. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry. 1976;33(12):1453–60.

    Article  PubMed  CAS  Google Scholar 

  6. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with ADHD: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29(3):239–47.

    Article  PubMed  CAS  Google Scholar 

  7. Rösler M, Fischer R, Ammer R, et al. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with ADHD. Eur Arch Psychiatry Clin Neurosci. 2009;259(2):120–9.

    Article  PubMed  Google Scholar 

  8. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult ADHD using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754–63.

    Article  PubMed  Google Scholar 

  9. Faraone, SV. Understanding effect size. Medscape, posted 14 Feb 2008; www.medscape.org/viewarticle/569729. Accessed 20 Sep 2011.

  10. Ginsberg L, Katic A, Adeyi B, et al. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with ADHD stratified by baseline severity. Curr Med Res Opin. 2011;27(6):1097–107.

    Google Scholar 

  11. Biederman J, et al. Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD. Eur Neuropsychopharmacol. 2011;21(7):508–15.

    Google Scholar 

  12. Brown TE, Brams M, Gao J, et al. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of ADHD in adults. Postgrad Med. 2010;122(5):7–17.

    Article  PubMed  Google Scholar 

  13. Barkley RA, Fischer M. Predicting impairment in major life activities and occupational functioning in hyperactive children as adults: self-reported executive function (EF) deficits versus EF tests. Dev Neuropsychol. 2011;36(2):137–61.

    Article  PubMed  Google Scholar 

  14. Bejerot S, Rydén EM, Arlinde CM. Two-year outcome of treatment with central stimulant medication in adult ADHD: a prospective study. J Clin Psychiatry. 2010;71(12):1590–7.

    Article  PubMed  CAS  Google Scholar 

  15. Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med. 2010;122(1):184–91.

    Article  PubMed  Google Scholar 

  16. Markowitz JS, Patrick KS. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol. 2008;28(3 suppl 2):S54-61. Review.

    Google Scholar 

  17. Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2008;28(3 suppl 2):S46–53. Review.

    Google Scholar 

  18. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121.

    Google Scholar 

  19. Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry. 1998;3:386–96.

    Article  PubMed  CAS  Google Scholar 

  20. Schiffer WK, Volkow ND, Fowler JS, et al. Therapeutic doses of amphetamine and methylphenidate differentially increase synaptic and extracellular dopamine. Synapse. 2006;59:243–51.

    Article  PubMed  CAS  Google Scholar 

  21. Spencer TJ, Adler LA, McGough JJ, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1380–7.

    Article  PubMed  CAS  Google Scholar 

  22. Spencer TJ, Mick E, Surman CB, et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord. 2011;15(4):286–94.

    Article  PubMed  Google Scholar 

  23. Volkow ND. Stimulant medications: how to minimize their reinforcing effects? Am J Psychiatry. 2006;163:359–61.

    Article  PubMed  Google Scholar 

  24. Gerhard T, Winterstein AG, Olfson M, et al. Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD. Pharmacoepidemiol Drug Saf. 2010;19(5):457–64.

    PubMed  CAS  Google Scholar 

  25. Biederman J, Mick E, Surman C, et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with ADHD. J Clin Psychopharmacol. 2010;30(5):549–53.

    Article  PubMed  CAS  Google Scholar 

  26. Chobanian AV, Bakris GI, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52

    Google Scholar 

  27. Cooney MT, Vartiainen E, Laatikainen T, Juolevi A, Dudina A, and Graham IM. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J. 2010;159(4):612–19.e3.

    Google Scholar 

  28. Jouven X, Empana JP, Escolano S, et al. Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol. 2009;103(2):279–83.

    Article  PubMed  Google Scholar 

  29. Fox K, Borer JS, Camm AJ, et al. Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50(9):823–30.

    Google Scholar 

  30. Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122:451–3.

    Article  PubMed  Google Scholar 

  31. Adler LA, Weisler RH, Goodman DW, et al. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with ADHD. J Clin Psychiatry. 2009;70(12):1652–61.

    Article  PubMed  CAS  Google Scholar 

  32. Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention deficit hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry. 2011;50(10):978–90.

    Article  PubMed  Google Scholar 

  33. Biederman J, Mick E, Surman C, et al. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with ADHD. BMC Psychiatry. 2007;7(1):49.

    Article  PubMed  Google Scholar 

  34. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with ADHD. Biol Psychiatry. 2008;63(10):981–9.

    Article  PubMed  CAS  Google Scholar 

  35. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with ADHD. J Clin Psychiatry. 2005;66(2):253–9.

    Article  PubMed  Google Scholar 

  36. Weisler RH, Biederman J, Spencer TJ, Wilens TE. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):35–43.

    PubMed  Google Scholar 

  37. Nissen S. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354(14):1445–8.

    Article  PubMed  CAS  Google Scholar 

  38. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medication for ADHD: a scientific statement from the American Heart Association council on cardiovascular disease in the young congenital cardiac defects committee and the council on cardiovascular nursing. Circulation. 2008;117(8):2407–23.

    Article  PubMed  Google Scholar 

  39. Villalba L, Racoosin J. Postmarketing safety review of sudden death during treatment with drugs used to treat ADHD. Food Drug Admin 2006;45:1294–1303.

    Google Scholar 

  40. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896–904.

    Article  PubMed  CAS  Google Scholar 

  41. McCarthy S, Cranswick N, Potts L, et al. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009;32(11):1089–96.

    Article  PubMed  Google Scholar 

  42. Olfson M, Huang C, Gerhard T, et al. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(2):147–56.

    Article  PubMed  Google Scholar 

  43. Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127(6):1102–10.

    Article  PubMed  Google Scholar 

  44. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with ADHD. Pediatrics. 2007;120(6):e1494–501.

    Article  PubMed  Google Scholar 

  45. Winterstein AG, Gerhard T, Shuster J, Saidi A. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics. 2009;124(1):e75–80.

    Article  PubMed  Google Scholar 

  46. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011;306(24):2673–83. doi:10.1001/jama.2011.1830.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, 185 Alewife Brook Parkway, Suite 2000, Cambridge, MA, 02138, USA

    Paul Hammerness M.D.

Authors
  1. Paul Hammerness M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Hammerness M.D. .

Editor information

Editors and Affiliations

  1. Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School, Alewife Brook Parkway, Suite 2000 185, Cambridge, 02138, USA

    Craig B.H. Surman

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Hammerness, P. (2013). Stimulant Pharmacotherapy for Adults with ADHD. In: Surman, C. (eds) ADHD in Adults. Current Clinical Psychiatry. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-248-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-248-3_5

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-247-6

  • Online ISBN: 978-1-62703-248-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation